Novo Net Debt vs Retained Earnings Analysis
| NVO Stock | USD 124.02 5.19 4.02% |
Novo Nordisk financial indicator trend analysis is infinitely more than just investigating Novo Nordisk AS recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novo Nordisk AS is a good investment. Please check the relationship between Novo Nordisk Net Debt and its Retained Earnings accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.
Net Debt vs Retained Earnings
Net Debt vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novo Nordisk AS Net Debt account and Retained Earnings. At this time, the significance of the direction appears to have strong relationship.
The correlation between Novo Nordisk's Net Debt and Retained Earnings is 0.68. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Novo Nordisk AS, assuming nothing else is changed. The correlation between historical values of Novo Nordisk's Net Debt and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Novo Nordisk AS are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Net Debt i.e., Novo Nordisk's Net Debt and Retained Earnings go up and down completely randomly.
Correlation Coefficient | 0.68 |
| Relationship Direction | Positive |
| Relationship Strength | Significant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Novo Nordisk's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novo Nordisk AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At this time, Novo Nordisk's Selling General Administrative is very stable compared to the past year. As of the 2nd of May 2024, Sales General And Administrative To Revenue is likely to grow to 0.04, while Tax Provision is likely to drop about 12.8 B.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 117.1B | 148.5B | 196.5B | 206.3B | Total Revenue | 140.8B | 177.0B | 232.3B | 243.9B |
Novo Nordisk fundamental ratios Correlations
Click cells to compare fundamentals
Novo Nordisk Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Novo Nordisk fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 125.6B | 144.9B | 194.5B | 241.3B | 314.5B | 330.2B | |
| Short Long Term Debt Total | 4.5B | 10.4B | 26.6B | 25.8B | 27.0B | 28.4B | |
| Other Current Liab | 15.8B | 18.4B | 21.8B | 103.9B | 30.0B | 31.5B | |
| Total Current Liabilities | 59.0B | 70.3B | 99.5B | 120.9B | 169.7B | 178.1B | |
| Total Stockholder Equity | 57.6B | 63.3B | 70.7B | 83.5B | 106.6B | 111.9B | |
| Property Plant And Equipment Net | 50.6B | 50.3B | 55.4B | 66.7B | 91.0B | 95.5B | |
| Net Debt | (11.0B) | (2.4B) | 15.9B | 13.1B | 12.6B | 13.2B | |
| Retained Earnings | 57.8B | 63.8B | 72.0B | 80.6B | 104.8B | 110.1B | |
| Cash | 15.5B | 12.8B | 10.7B | 12.7B | 14.4B | 8.1B | |
| Non Current Assets Total | 63.2B | 79.1B | 108.9B | 133.1B | 174.8B | 183.6B | |
| Non Currrent Assets Other | 841M | 674M | 267M | 206M | 1.4B | 1.4B | |
| Cash And Short Term Investments | 15.5B | 12.8B | 17.5B | 23.6B | 30.2B | 31.7B | |
| Net Receivables | 29.2B | 32.2B | 46.8B | 57.5B | 75.3B | 79.0B | |
| Common Stock Shares Outstanding | 4.8B | 4.7B | 4.6B | 4.5B | 4.5B | 3.7B | |
| Liabilities And Stockholders Equity | 125.6B | 144.9B | 194.5B | 241.3B | 314.5B | 330.2B | |
| Non Current Liabilities Total | 9.0B | 11.3B | 24.2B | 36.8B | 38.3B | 40.2B | |
| Inventory | 17.6B | 18.5B | 19.6B | 24.4B | 31.8B | 33.4B | |
| Total Liab | 68.0B | 81.6B | 123.8B | 157.8B | 207.9B | 218.3B | |
| Property Plant And Equipment Gross | 30.3B | 50.3B | 95.9B | 111.4B | 138.6B | 145.5B | |
| Total Current Assets | 62.5B | 65.8B | 85.6B | 108.2B | 139.6B | 146.6B | |
| Accumulated Other Comprehensive Income | (694M) | (911M) | (1.7B) | 2.4B | 1.3B | 1.3B | |
| Short Term Debt | 1.5B | 7.5B | 13.7B | 1.5B | 6.5B | 6.8B | |
| Intangible Assets | 5.8B | 20.7B | 38.8B | 46.3B | 55.9B | 58.7B | |
| Other Current Assets | 188M | 2.3B | 1.7B | 2.7B | 2.3B | 1.5B | |
| Accounts Payable | 6.4B | 5.7B | 8.9B | 15.6B | 25.6B | 26.9B | |
| Common Stock Total Equity | 500M | 490M | 480M | 470M | 423M | 493.1M | |
| Common Stock | 480M | 470M | 462M | 456M | 451M | 478.4M | |
| Other Liab | 6.0B | 8.4B | 11.3B | 12.5B | 14.4B | 15.1B | |
| Property Plant Equipment | 50.6B | 50.3B | 55.4B | 66.7B | 76.7B | 80.5B | |
| Current Deferred Revenue | 35.3B | 38.7B | 55.2B | 107.6B | 123.7B | 129.9B | |
| Other Assets | 5.0B | 6.5B | 8.9B | 13.4B | 15.4B | 16.2B | |
| Net Tangible Assets | 51.8B | 42.7B | 27.6B | 32.1B | 36.9B | 37.0B | |
| Long Term Investments | 1.8B | 1.6B | 1.4B | 1.3B | 1.7B | 1.5B | |
| Short Long Term Debt | 659M | 6.7B | 12.9B | 480M | 5.3B | 2.9B | |
| Long Term Debt Total | 3.0B | 2.9B | 13.0B | 24.3B | 28.0B | 29.4B |
Novo Nordisk Investors Sentiment
The influence of Novo Nordisk's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novo. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Novo Nordisk's public news can be used to forecast risks associated with an investment in Novo. The trend in average sentiment can be used to explain how an investor holding Novo can time the market purely based on public headlines and social activities around Novo Nordisk AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Novo Nordisk's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novo Nordisk's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novo Nordisk's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novo Nordisk.
Novo Nordisk Implied Volatility | 61.36 |
Novo Nordisk's implied volatility exposes the market's sentiment of Novo Nordisk AS stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novo Nordisk's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novo Nordisk stock will not fluctuate a lot when Novo Nordisk's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novo Nordisk in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novo Nordisk's short interest history, or implied volatility extrapolated from Novo Nordisk options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Novo Stock analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Novo Nordisk's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.631 | Dividend Share 9.4 | Earnings Share 2.67 | Revenue Per Share 51.812 | Quarterly Revenue Growth 0.37 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.